OSCOTEC Inc.

오스코텍 · 039200

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$1.2B (₩1.6T)

Overview

OSCOTECInc is a South Korean biotech company, listed on KOSDAQ, that develops synthetic small-molecule drugs for conditions such as arthritis and cancer, while also supplying functional health-food ingredients and dental bone-graft materials used in dental procedures.

Its products reach domestic pharmaceutical companies, dentists, and health-food manufacturers. The business runs three parallel lines, drug discovery, functional ingredients, and dental bone grafts, with a targeted lung-cancer compound that has been approved by both the Korean drug regulator and the US FDA as a first-line treatment, either alone or in combination.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025
Revenue · FY2025
US$72.3M
▲ +193.6% YoY
Operating profit · FY2025
US$37.7M
Turned profitable
Net income · FY2025
US$39.4M
Turned profitable

Revenue

  • FY2023US$3.6M
  • FY2024US$24.6M
  • FY2025US$72.3M

Operating profit

  • FY2023−US$23.7M
  • FY2024−US$2M
  • FY2025US$37.7M

Net income

  • FY2023−US$20.6M
  • FY2024−US$1.2M
  • FY2025US$39.4M

Key ratios (FY2025)

ROE
29.1%
Debt/Eq
23.0%
Op. margin
52.2%
Net margin
54.5%
Rev. YoY
▲ +193.6%

Why it matters

The lung-cancer compound was licensed out to a domestic pharmaceutical company through a technology-transfer agreement, making licensing a key part of its drug-development model.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-06-12 (KST). · FX: 1 USD ≈ ₩1,380 (2026-06-01).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.